Verona Pharma PLC
I9SA
Company Profile
Business description
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Contact
3 More London Riverside
LondonSE1 2RE
GBRT: +44 2032834200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
209
Stocks News & Analysis
stocks
The lessons behind the best performing stock over the last 80 years
4 factors that led to the incredible returns of Philip Morris.
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,055.30 | 34.60 | -0.43% |
| CAC 40 | 8,171.47 | 56.90 | 0.70% |
| DAX 40 | 23,288.06 | 92.64 | -0.40% |
| Dow JONES (US) | 41,964.63 | 383.32 | 0.92% |
| FTSE 100 | 8,706.66 | 1.43 | 0.02% |
| HKSE | 24,771.14 | 30.57 | 0.12% |
| NASDAQ | 17,750.79 | 246.67 | 1.41% |
| Nikkei 225 | 37,751.88 | 93.54 | -0.25% |
| NZX 50 Index | 12,098.34 | 52.41 | 0.44% |
| S&P 500 | 5,675.29 | 60.63 | 1.08% |
| S&P/ASX 200 | 7,828.30 | 32.10 | -0.41% |
| SSE Composite Index | 3,426.43 | 3.33 | -0.10% |